Journal
MOLECULAR NEURODEGENERATION
Volume 9, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1750-1326-9-2
Keywords
Alzheimer's disease; Amyloid beta; Apolipoprotein E; Apolipoprotein E/amyloid beta complex; Oligomeric amyloid beta; Lipoprotein; Lipidation
Categories
Funding
- NIH/NIA [P01AG030128]
- Alzheimer's Association Grant [ZEN-08-899000]
- University of Illinois at Chicago Center for Clinical and Translational Science Grant [UL1RR029879]
- Alzheimer's Drug Discovery Foundation Grant
Ask authors/readers for more resources
The APOE4 allele of apolipoprotein E (apoE) is the greatest genetic risk factor for Alzheimer's disease (AD) compared to APOE2 and APOE3. Amyloid-beta (A beta), particularly in a soluble oligomeric form (oA beta), is considered a proximal cause of neurodegeneration in AD. Emerging data indicate that levels of soluble oA beta are increased with APOE4, providing a potential mechanism of APOE4-induced AD risk. However, the pathway(s) by which apoE4 may increase oA beta levels are unclear and the subject of continued inquiry. In this editorial review, we present the hypothesis that apoE isoform-specific interactions with A beta, namely apoE/A beta complex, modulate A beta levels. Specifically, we propose that compared to apoE3, apoE4-containing lipoproteins are less lipidated, leading to less stable apoE4/A beta complexes, resulting in reduced apoE4/A beta levels and increased accumulation, particularly of oA beta. Evidence that support or counter this argument, as well as the therapeutic significance of this pathway to neurodegeneration, are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available